
Humanoid robot performs medical procedures via remote control
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my CYBERGUY.COM/NEWSLETTER.
UCSD equipped a Unitree G1 humanoid robot with Inspire Gen4 robotic hands and developed a bimanual teleoperation system for it as well. Both allow it to perform seven varied medical procedures using a remote control operated by a human using foot pedals, HTC Vive trackers, and motion-capture cameras.
These tasks the robot carried out ranged from physical exams like auscultation and palpation, to emergency procedures such as Bag Valve Mask ventilation and endotracheal intubation. Some of them even required a great deal of precision, like ultrasound-guided injections.
There were some challenges with force control and sensor sensitivity, but the robot managed to carry out most tasks given to it with accuracy.
For examinations, it successfully used a stethoscope and performed basic physical examinations. In these tests, performance was hindered by limitations in sensor feedback and hand design. For emergency care, it achieved consistent ventilation. However, it required human assistance to maintain the necessary seal and force required for intubation.
When it came to needle procedures, it performed ultrasound-guided injections. It achieved a 70% success rate when performed by non-clinicians, demonstrating its potential for training purposes. Trials showed issues with needle control and orientation during suturing, indicating that the haptic feedback mechanisms need improvement.
This is the first major study to add humanoid robots to hospital work systems. With aging populations and ongoing labor shortages, these adaptable robots could support routine and emergency tasks in hospital settings. This robot could take immense pressure off medical staff. The versatility and ability to be remotely controlled make it particularly appealing for settings that require rapid response and tools that can carry out a wide range of tasks.
If you've ever waited too long in an ER, struggled to book a specialist appointment, or worried about overworked healthcare providers, this research should catch your attention. Humanoid robots like the Unitree G1 aren't replacing doctors, but they could support them in real, practical ways. From performing emergency procedures in remote areas to helping with routine physical exams in crowded hospitals, these robots could ease bottlenecks and improve care access.
For patients, that could mean shorter wait times, faster treatment, and safer hospital environments where medical teams are less stretched. For families in rural or underserved areas, this technology could offer critical care support where medical staff is limited. And for healthcare workers, it could bring much-needed relief by taking on repetitive or physically taxing tasks.
While the tech is still evolving, these early results suggest a future where hospitals have robotic teammates, not just tools, helping deliver faster, smarter care.
While humanoid robots like the Unitree G1 are not ready to fully replace humans, they're steadily proving how capable they are in medical environments. The researchers just need to solve issues like force control, sensitivity, and dexterity. Once they do, we will see these robots in operating rooms around the world assisting with surgeries. They will make our struggling healthcare systems far more resilient and accessible.
Would you let a humanoid robot handle your healthcare needs? Let us know by writing us at Cyberguy.com/Contact.
Sign up for my FREE CyberGuy ReportGet my best tech tips, urgent security alerts, and exclusive deals delivered straight to your inbox. Plus, you'll get instant access to my Ultimate Scam Survival Guide - free when you join my CYBERGUY.COM/NEWSLETTER.
Copyright 2025 CyberGuy.com. All rights reserved.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
US securities regulator announces AI task force
(Reuters) -The U.S. Securities and Exchange Commission said on Friday that it is creating an artificial intelligence task force to lead the agency's efforts to "enhance innovation and efficiency" in its operations. Valerie Szczepanik, who has been named the SEC's chief AI officer, will lead the task force, the regulator said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Crypto's $10 Billion Shakeout: Why Bitcoin's Rally Just Hit a Wall
Bitcoin (BTC-USD) extended its slide for a fifth straight session, dipping as much as 2.2% to $113,979 its lowest level in nearly a month as investor enthusiasm continues to cool following July's all-time high. That peak, which saw Bitcoin touch $123,200 just before President Donald Trump signed the country's first crypto regulatory framework into law, now feels like a distant memory. Ether also retreated sharply, falling 4.5% to $3,567, while the broader digital asset market gave back some of its recent gains after briefly crossing a $4 trillion market cap milestone last month. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The rally had been fueled by blockbuster ETF flows Bitcoin products attracted $6 billion in net inflows in July (third-best on record), while Ether ETFs brought in $5.4 billion, marking their strongest month yet. But momentum is showing signs of fatigue. Bitcoin's Coinbase premium a real-time measure of US investor appetite flipped negative this week for the first time in two months, according to CryptoQuant. Futures open interest on CME has dropped 13% for Bitcoin and 21% for Ether from their July peaks. These shifts suggest that institutions could be taking a more cautious stance as Q3 gets underway. Traders appear to be repositioning quickly. Over $800 million in leveraged long positions were liquidated in the past 24 hours alone including $251 million tied to Ether and $200 million to Bitcoin, based on Coinglass data. At the same time, downside protection is gaining traction. Nick Forster, founder of noted that Bitcoin's 30-day options skew has swung from +3% to -1.5%, pointing to rising demand for puts over calls. Roughly $10 billion in BTC was sold OTC on July 15, triggering a 4% price dip, he added. Miners also sold off about 15,000 BTC after the record high. Meanwhile, Coinbase (NASDAQ:COIN) shares fell as much as 17% after Q2 revenue came in below estimates, underscoring a broader pullback in retail and institutional engagement alike. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Why Figma Stock Skyrocketed 250% This Week
Key Points Figma stock surged 247% after its IPO, hitting a market cap close to $60 billion. Impressive recent growth (more than 40% YOY) and widespread adoption highlight the platform's strength. At this valuation, investors must believe Figma can sustain rapid growth and fend off intensifying AI-driven competition. 10 stocks we like better than Figma › Shares of Figma (NYSE: FIG) exploded this week after its public debut on Thursday. The stock is currently trading 253% higher than its initial public offering (IPO) price as of 3:17 p.m. ET. The extreme leap comes as the S&P 500 lost 2.4%, and the Nasdaq-100 lost 2.2% amid new tariffs and weak jobs data. Figma, which offers a web-based design platform that is used to create websites and apps, IPOed on Thursday at $33 a share and is now trading above $118. The huge IPO eclipsed even the recent success of Circle Internet, which saw its stock triple in the first few weeks. Figma's stock is red hot The company has now reached a valuation of nearly $60 billion. That is a pretty hefty valuation, given the company's 2024 sales of under $750 million. Granted, it has grown its top line by more than 40% in both of the last two years. That's pretty impressive. I have doubts, however, about how long this trajectory can last. The company touts that "95% of the Fortune 500" used Figma in March of this year. While that number lends clout to the company and the quality of its product, it's a double-edged sword. It calls into question how much the company can continue growing its enterprise revenue if it is already so ubiquitous among the most important companies in the world. I have serious doubts about the strength of Figma's moat and its ability to defend it in a hyper-competitive landscape actively being transformed by artificial intelligence (AI), at least at its current valuation. It would need to continue to deliver 40% growth for years to justify its current valuation and continue to offer investors a solid return. Should you buy stock in Figma right now? Before you buy stock in Figma, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Figma wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Figma Stock Skyrocketed 250% This Week was originally published by The Motley Fool